Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang) Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, VISHNYAKOVA, ELENA VLADIMIROVNA, who is the busiest examiner for the portfolio. The prosecution is conducted within a distinct art unit, ensuring that the application is reviewed by a department with relevant technical expertise.
With VISHNYAKOVA, ELENA VLADIMIROVNA as the only examiner responsible for the pending action, the company can develop a highly consistent approach to its patent prosecution. The practitioner should focus on the specific preferences and examination history of the busiest examiner to improve the efficiency of the response. This level of concentration within the Biotechnology & Pharmaceuticals sector can lead to more predictable outcomes.
The presence of the pending office action in a distinct art unit indicates a focused patent strategy for the company. By understanding the standards and practices of this specific unit, the practitioner can better anticipate the types of objections that may arise during the review. Monitoring the progress of the pending action is essential for the successful management of the company's intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VISHNYAKOVA, ELENA VLADIMIROVNA | 1 | 68.3% | +46.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717878 | SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717878 | SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103DP | Non-Final OA | — | Pending | Jun 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCspc Zhongqi Pharmaceutical Technology(Shijiazhuang) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Elena Vladimirovna Vishnyakova has the most, with 1 of Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
